Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial

NCT06864533 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06864533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2019
Completion date
September 1, 2031
Enrollment
315 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, gleason score, prostate cancer, radiation therapy